Equity Profile

NVS

Novartis AG

Health CarePharmaceuticals$281.5B

Apr28Tue

Post-Earnings Recap

ReportedQ1-2026Pre-Market1:00 AM EDT

Novartis Misses on EPS, Stock Down 0.88%

Metric	Actual	Expected	Surprise
EPS	$1.99	$2.07	-5.60%
Revenue	N/A	$13.5B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Novartis Misses on EPS, Stock Down 0.88%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.99	$2.07	-5.60%
Revenue	N/A	$13.5B	N/A

Management Commentary

Tone: Cautiously Optimistic

Management expressed a commitment to their product pipeline and innovation. They acknowledged current market challenges but remained cautiously optimistic about future prospects.

We are focused on maintaining our pipeline despite current challenges.

Our commitment to innovation remains strong as we navigate market dynamics.

What It Means

The earnings report indicates that Novartis is facing challenges in meeting earnings expectations, as reflected by the EPS miss. The stock's slight decline of 0.88% suggests that investors may be concerned about the company's short-term performance. Without revenue figures or updated guidance, uncertainty remains about future growth prospects.

Company Snapshot

Novartis AG (NVS) is a global healthcare company focused on developing and manufacturing pharmaceuticals. With a market cap of $275 billion, it plays a crucial role in the healthcare sector, addressing various medical needs through innovative treatments.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$2.07

Revenue

Total revenue reflects the company's sales performance and market demand for its products, which is essential for growth.

$13.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.66%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q4-2025, Novartis reported an EPS of $2.03, beating expectations by 2.11%. The stock reacted positively, gaining 2.04% the following day.

Management Promises & Guidance

Continue to focus on innovative drug development.
Maintain cost management to improve profitability.
Expand market presence in emerging markets.

Expectations

Wall Street Expectations

Analysts expect Novartis to report steady earnings and revenue, with a consensus EPS of $2.07 and revenue of $13.5 billion. Investors are keen to see if the company can maintain its growth trajectory.

Bull Case

If Novartis exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products and effective management strategies.

Bear Case

Conversely, if the company misses earnings targets or provides weak guidance, it may raise concerns about its competitive position and market dynamics.

Key Metrics to Watch

EPS

$2.07

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue

$13.5B

Total revenue reflects the company's sales performance and market demand for its products, which is essential for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Novartis achieve an EPS of $2.07 or higher?

This figure is critical as it directly impacts investor confidence and stock performance.

What guidance will management provide for revenue growth?

Future revenue expectations will influence market sentiment and the company's growth outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Novartis' ability to innovate and capture market share, leading to potential upside in earnings.

Supporting Evidence

The company has a history of beating EPS estimates, with an 88% success rate in the last eight quarters.

Options pricing suggests a larger move than historical averages, indicating potential for a surprise.

Recent positive developments in drug approvals could drive unexpected revenue growth.

Key Risk

If Novartis reports an EPS below $2.00, it could challenge the optimistic growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching how Novartis navigates competitive pressures and manages its product pipeline.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $2.00 would raise concerns about profitability and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±5.44%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, indicating that investors anticipate volatility around the earnings report.

Options are pricing ±5.8% while NVS has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

20.2%

Calls (57K)P/C Ratio: 3.92Puts (222K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novartis beats expectations, history suggests a potential average one-day move of +2.66%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the details.

Miss

Should the company miss earnings expectations, history indicates an average one-day move of -4.42%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new drug approvals and their expected market impact.
2Any changes in guidance for revenue growth in emerging markets.
3Insights into cost management strategies and their effect on margins.
4Discussion on competitive pressures and how Novartis plans to address them.
5Management's outlook on future product launches and pipeline developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$2.07

Revenue

Total revenue reflects the company's sales performance and market demand for its products, which is essential for growth.

$13.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.66%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q4-2025, Novartis reported an EPS of $2.03, beating expectations by 2.11%. The stock reacted positively, gaining 2.04% the following day.

Management Promises & Guidance

Continue to focus on innovative drug development.
Maintain cost management to improve profitability.
Expand market presence in emerging markets.

Expectations

Wall Street Expectations

Bull Case

If Novartis exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products and effective management strategies.

Bear Case

Conversely, if the company misses earnings targets or provides weak guidance, it may raise concerns about its competitive position and market dynamics.

Key Metrics to Watch

EPS

$2.07

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue

$13.5B

Total revenue reflects the company's sales performance and market demand for its products, which is essential for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Novartis achieve an EPS of $2.07 or higher?

This figure is critical as it directly impacts investor confidence and stock performance.

What guidance will management provide for revenue growth?

Future revenue expectations will influence market sentiment and the company's growth outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Novartis' ability to innovate and capture market share, leading to potential upside in earnings.

Supporting Evidence

The company has a history of beating EPS estimates, with an 88% success rate in the last eight quarters.

Options pricing suggests a larger move than historical averages, indicating potential for a surprise.

Recent positive developments in drug approvals could drive unexpected revenue growth.

Key Risk

If Novartis reports an EPS below $2.00, it could challenge the optimistic growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching how Novartis navigates competitive pressures and manages its product pipeline.

Bull Confirmed If

An EPS of $2.10 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $2.00 would raise concerns about profitability and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±5.44%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, indicating that investors anticipate volatility around the earnings report.

Options are pricing ±5.8% while NVS has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

20.2%

Calls (57K)P/C Ratio: 3.92Puts (222K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novartis beats expectations, history suggests a potential average one-day move of +2.66%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the details.

Miss

Should the company miss earnings expectations, history indicates an average one-day move of -4.42%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new drug approvals and their expected market impact.
2Any changes in guidance for revenue growth in emerging markets.
3Insights into cost management strategies and their effect on margins.
4Discussion on competitive pressures and how Novartis plans to address them.
5Management's outlook on future product launches and pipeline developments.